Skip to main content
SpringerLink
Log in

Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate]

  • Published:
Cellular and Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Rasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor which has been developed as an anti-Parkinson drug. In controlled monotherapy and as adjunct to L-dopa it has shown anti-Parkinson activity. In cell culture (PC-12 and neuroblastoma SH-SY5Y cells) it exhibits neuroprotective and antiapoptotic activity against several neurotoxins (SIN-1, MPTP, 6-hydroxydopamine and N-methyl-(R)-salsolinol) and ischemia. In vivo, it reduces the sequelae of traumatic brain injury in mice and speeds their recovery. The neuroprotective activity of rasagaline does not result from MAO B inhibition, since its S-enantiomer, TVP1022, which has 1000-fold weaker MAO inhibitory activity, exhibits similar neuroprotective properties. Introduction of a carbamate moiety into the rasagiline molecule to confer cholinesterase inhibitory activity for the treatment of Alzheimer's disease, resulted in compounds TV3326 [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] and its S-enantiomer TV3279 [(N-Propargyl-(3S) Aminoindan-5-YL)-Ethyl Methyl Carbamate], which retain the neuroprotective activities of rasagiline and TVP1022. They also antagonize scopolamine-induced impairments in spatial memory. In addition, TV3326 exhibits brain-selective MAO A and B inhibitory activity after chronic administration and has antidepressant-like activity in the forced swim test. This is associated with an increase in brain levels of serotonin. The antiapoptotic activity of these propargylamine-containing derivatives may be related to their ability to delay the opening of voltage-dependent anion channels (VDAC), which are part of the mitochondrial permeability transition pore. The propargylamine moiety is responsible for the increase in the mitochondrial family of Bcl-2 proteins, prevention in the fall in mitochondrial membrane potential, prevention of the activation of caspase 3, and of translocation of glycerlaldehyde-3-phosphate dehydrogenase from the cytoplasm to the nucleus. The latter processes are closely associated with neurotoxin-induced apoptosis. Rasagiline interacts with and prevents the binding of PK11195 to the pro-apoptotic peripheral benzodiazepine receptor, which together with Bcl-2, hexokinase, porin, and adenine nucleotide translocator constitutes part of the VDAC. Furthermore, rasagiline, TV3326 and TV3279 are able to influence the processing of amyloid precursor protein by activation of alpha-secretase and increasing the release of soluble alpha APP in rat PC-12 and human neuroblastoma SH-SY5Y cells and in rat and mice cortex and hippocampus. This process has been shown to involve the upregulation of PKC and MAP kinase. It is quite likely that the induction of Bcl-2 and activation of PKC by rasagiline and TV3326 is closely linked to the anti-apototic action of these drugs and their ability to process APP by activation of alpha-secretase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Abu-Raya, S.,Blaugrund, E.,Tremblover, V.,Shilderman-Bloch, E.,Shohami, E., andLazarovici, P. (1999). Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentated PC12 cells against oxygen-glucose deprivation. J. Neurosci. Res. 58: 456-463.

    Google Scholar 

  • Anderson, J. P.,Esch, F. S.,Keim, P. S.,Sambamurti, K.,Lieberburg, I., andRobakis, N. K. (1991). Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neurosci. Lett. 128: 126-128.

    Google Scholar 

  • Bastar, I.,Seckin, S.,Uysal, M., andAykac-Toker G. (1998). Effect of streptozotocin on glutathione and lipid peroxide levels in various tissues of rats. Res. Commun. Mol. Pathol. Pharmacol. 102: 265-272.

    Google Scholar 

  • Buxbaum, J. D.,Oishi, M.,Chen, H. I.,Pinkas-Kramarski, R.,Jaffe, E. A.,Gandy, S. E., andGreengard, P. (1992). Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Nat. Acad. Sci. U.S.A. 89: 10075-10078.

    Google Scholar 

  • Buxbaum, J. D.,Koo, E. H., andGreengard, P. (1993). Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc. Natl. Acad. Sci. U.S.A. 90: 9195-9198.

    Google Scholar 

  • Carlile, G. W.,Chalmers-Redman, R. M.,Tatton, N. A.,Pong, A.,Borden, K. E., andTatton, W. G. (2000). Reduced apoptosis after nerve growth factor and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol. Pharmacol. 57: 2-12.

    Google Scholar 

  • Carrillo, M. C.,Minami, C.,Kitani, K.,Maruyama, W.,Ohashi, K.,Yamamoto, T.,Naoi, M.,Kanai, S., andYoudim, M. B. (2000). Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 67(5): 577-585.

    Google Scholar 

  • Davis-Salinas, J.,Saporito-Irwin, S. M.,Donovan, F. M.,Cunningham, D. D., andVan Nostrand, W. E. (1994). Thrombin receptor activation induces secretion and on amyloidogenic processing of amyloid beta-protein precursor. J. Biol. Chem. 269: 22623-22627.

    Google Scholar 

  • Drigues, N.,Poltyrev, T.,Weinstock, M., andYoudim, M. B. H. (2000). Gene expression and behavioral profile of different types of anti and nonantidepressant drugs. Neurosci. Lett. Suppl. 55: S15.

    Google Scholar 

  • Duelli, R.,Schrőck, H.,Kuschinsky, W., andHoyer, S. (1994). Intra-cerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int. J. Dev. Neurosci. 12: 737-743.

    Google Scholar 

  • Edwards, J. G. (1995). Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants? CNS Drugs 4: 141-159.

    Google Scholar 

  • Eschi, F. S., et al. (1990). Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248: 1122-1124.

    Google Scholar 

  • Filip, V., andKolibas, E. (1999). Selegiline in the treatment of Alzheimer's disease: A long-term randomized placebocontrolled trial. Czech and Slovak Senile. Dementia of Alzheimer Type Study Group. J. Psychiatry. Neurosci. 24(3): 234-243.

    Google Scholar 

  • Finberg, J. P.,Lamensdorf, I.,Commissiong, J. W., andYoudim, M. B. (1996). Pharmacology and neuroprotective properties of rasagiline. J. Neural Transm. Suppl. 48: 95-101.

    Google Scholar 

  • Finberg, J. P.,Tenne, M., andYoudim, M. B. (1981). Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmacol. 73(1): 65-74.

    Google Scholar 

  • Finberg, J.P., andYoudim, M.B. (1985). Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br. J. Pharmacol. 85(2): 541-546.

    Google Scholar 

  • Finberg, J. P.,Wang, J.,Bankiewicz, K.,Harvey-White, J.,Kopin, I. J., andGoldstein, D. S. (1998). Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(C)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J. Neural Transm. Suppl. 52: 279-285.

    Google Scholar 

  • Finberg, J. P.,Lamensdorf, I.,Weinstock, M.,Schwartz, M., andYoudim, M. B. (1999). Pharmacology of rasagiline (N-propargyl-1R-aminoindan) Adv. Neurol. 80: 495-499.

    Google Scholar 

  • Finberg, J. P.,Takeshima, T.,Johnston, J. M., andCommissiong, J. W. (1998). Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9(4): 703-707.

    Google Scholar 

  • Giacobini, E. (1998). Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future application. Neurochem. Int. 32: 413-419.

    Google Scholar 

  • Giacobini, E.,Mori, F., andLai, C. C. (1996). The effect of cholinesterase inhibitors on the ecretion of APPS from rat brain cortex. Ann. N.Y. Acad. Sci. 777: 393-398.

    Google Scholar 

  • Giacobini, E., andCuadra, G. (1994). Second and third generation cholinesterase inhibitors: From preclinical studies to clinical efficacy. In Giacobini, E., andBecker, R. (eds.), Alzheimer Disease: Therapeutic Strategies. Birkhauser Boston, Cambridge.

    Google Scholar 

  • Goggi, J.,Theofilopoulos, S.,Riaz, S. S.,Jauniaux, E.,Stern, G. M., andBradford, H. (2000). The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport 11(18): 3937-3941.

    Google Scholar 

  • Gorman, L. K.,Fu, D. A.,Hovda, D. A.,Murray, M., andTraystman, R. J. (1996). Effects of traumatic brain injury on the cholinergic system in the rat. J. Neurotrauma 13: 457-463.

    Google Scholar 

  • Guo, B. C., andXu, A. (2001). Bcl-2 over-expression and activation of protein kinase C suppress the trail-induced apoptosis in Jurkat T cells. Cell. Res. 11(2): 101-106.

    Google Scholar 

  • Heikkila, R. E.,Duvoisin, R. C.,Finberg, J. P., andYoudim, M. B. (1985). Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 116(3): 313-317.

    Google Scholar 

  • Huang, W.,Chen, Y.,Shohami, E., andWeinstock, M. (1999). Neuroprotective effect of rasagiline, a selective MAO-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366: 127-135.

    Google Scholar 

  • Kalir, A.,Sabbagh, A., andYoudim, M. B. (1981). Selective acetylenic “suicide” and reversible inhibitors of monoamine oxidase types A and B. Br. J. Pharmacol. 73(1): 55-64.

    Google Scholar 

  • Klatzo, I. (1967). Neuropathological aspects of brain edema. J. Neuropathol. Exp. Neurol. 26: 1-14.

    Google Scholar 

  • Koutsilieri, E.Scheller, C.,Sopper, S.,Gotz, M. E.,Gerlach, M.,Meulen, V., andRiederer, P. (2001). Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection. Eur. J. Pharmacol. 411: R1-R2.

    Google Scholar 

  • Krall, W. J.,Sramek, J. J., andCutler, N. R. (1999). Cholinesterase inhibitors: A therapeutic strategy in Alzheimer disease. Ann. Pharmacother. 33: 441-450.

    Google Scholar 

  • Lahiri, D. K.,Farlow, M. R.,Nurnberger, J. I., Jr., andGreig, N. H. (1997). Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann. N. Y. Acad. Sci. 826: 416-421.

    Google Scholar 

  • Lamensdorf, I.,Porat, S.,Simantov, R.,andFinberg, J.P. (1999). Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br. J. Pharmacol. 126: 997-1002.

    Google Scholar 

  • Lee, R. K., et al. (1995). Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc. Nat. Acad. Sci. U.S.A. 92: 8083-8087.

    Google Scholar 

  • Lombet, A.,Zujovic, V.,Kandouz, M.,Billardon, C.,Carvajal-Gonzalez, S.,Gompel, A., andRostene, W. (2001). Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation. Role of Bcl-2 protein family. Eur. J. Biochem. 268: 1352-1362.

    Google Scholar 

  • Maruyama, W.,Akao, Y.,Youdim, M. B., andNaoi, M. (2000b). Neurotoxins induce apoptosis in dopamine neurons: Protection by N-propargylamine-1(R)-and (S)-aminoindan, rasagiline and TV1022. J. Neural. Transm. Suppl. 60: 71-86.

    Google Scholar 

  • Maruyama, W.,Akao, Y.,Youdim, M. B.,Davis, B. A., andNaoi, M. (2001b). Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78: 727-735.

    Google Scholar 

  • Maruyama, W.,Yamamoto, T.,Kitani, K.,Carrillo,M. C.,Youdim, M., andNaoi, M. (2000a). Mechanism underlying anti-apoptotic activity of a (¡)deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. 116: 181-191.

    Google Scholar 

  • Maruyama, W.,Youdim, M. B., andNaoi, M. (2001a). Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann. N. Y. Acad. Sci. 939: 320-329.

    Google Scholar 

  • Mills, J., andReiner, P.B. (1999). Regulation of amyloid precursor protein cleavage. J. Neurochem. 72: 443-460.

    Google Scholar 

  • Mori, F.,Lai, C.,Fusi, F., andGiacobini, E. (1995). Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroprotection 6: 633-636.

    Google Scholar 

  • Naoi, M.,Maruyama, W.,Yagi, K., andYoudim, M. (2000). Anti-apoptotic function of L-(-)deprenyl (Selegiline) and related compounds. Neurobiology (Bp). 8: 69-80.

    Google Scholar 

  • Newman, S. C. (1999). The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample. J. Affect. Disord. 52: 169-176.

    Google Scholar 

  • Nitsch, R. M.,Slack, B. E.,Wurtman, R. J., andGrowdon, J. H. (1992). Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258: 304-307.

    Google Scholar 

  • Nitsch, R. M.,Slack, B. E.,Farber, S. A.,Borghesani, P. R.,Schulz, J. G.,Kim, C.,Felder, C. C.,Growdon, J. H.,andWurtman, R. J. (1993). Receptor-coupled amyloid precursor protein processing. Ann. N. Y. Acad. Sci. 695: 122-127.

    Google Scholar 

  • Nitsch, R. M.,Deng, M.,Growdon, J. H., andWurtman, R. J. (1996). Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J. Biol. Chem. 271: 4188-4194.

    Google Scholar 

  • Palmer, A. M.,Stratman, G. C.,Procter, A.W., andBowen, D. M. (1988). Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann. Neurol. 23: 616-620.

    Google Scholar 

  • Pakaski, M.,Rakonczay, Z., andKasa, P. (2001). Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro. Neurochem. Int. 38: 219-226.

    Google Scholar 

  • Parkinson Study Group. (2000). A Controlled Clinical Trial of Rasagiline in Early Parkinson's Disease. Am. Neurol. Assoc. Boston.

  • Rabey, J. M.,Sagi, I.,Huberman, M.,Melamed, E.,Korczyn, A.,Giladi, N.,Inzelberg, R.,Djaldetti, R.,Klein, C., andBerecz, G. (2000). Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol. 23: 324-330.

    Google Scholar 

  • Racchi, M., andGovoni, S. (1999). Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism. Trends Pharmacol. Sci. 20: 418-423.

    Google Scholar 

  • Racchi, M.,Schmidt, B.,Koenig, G., andGovoni, S. (1999). Treatment with metrifonate promotes soluble amyloid precursor protein release from SH-SY5Y neuroblastoma cells, in Alzheirmer's Disease and Related Disorders. In Eqbal, K., (eds.), Etiology, Pathogenesis and Therapeutics. Wiley, New York, pp. 679-687.

    Google Scholar 

  • Sagi, Y.,Weinstock, M., andYoudim, M. B. H. (2001). Neuroprotection and neurorescue of nigrostriatal dopamine neurons in MPTP treated mice by rasagiline and TV3326. Synapse. 8: 197.

    Google Scholar 

  • Sano, M.,Ernesto, C.,Thomas, R. G.,Klauber, M. R.,Schafer, K.,Grundman, M.,Woodbury, P.,Growdon, J.,Cotman, C. W.,Pfeiffer, E.,Schneider, L. S., andThal, L. J. (1997). Controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease. New Engl. J. Med. 336: 1216-1222.

    Google Scholar 

  • Sisodia, S. S.,Koo, E. H.,Beyreuther, K.,Unterbeck, A., andPrice, D. L. (1990). Evidence that betaamyloid protein in Alzheimer's disease is not derived by normal processing. Science 248: 492-495.

    Google Scholar 

  • Slack, B. E.,Breu, J.,Muchnicki, L., andWurtman, R. J. (1997). Rapid stimulation of amyloid precursor protein release by epidermal growth factor: Role of protein kinase C. Biochem. J. 327: 245-249.

    Google Scholar 

  • Smith, S. L.,Andrus, P. K.,Zhang, J. R., andHall, E. D. (1994). Direct measurement of hydroxyl radicals, lipid peroxidation, and blood-brain barrier disruption following unilateral cortical impact head injury in the rat. J. Neurotrauma 11: 393-404.

    Google Scholar 

  • Speiser, Z.,Katzir, O.,Rehavi, M.,Zabarski, T., andCohen, S. (1998a). Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol. Biochem. Behav. 60: 387-393.

    Google Scholar 

  • Speiser, Z.,Levy, R., andCohen, S. (1998b). Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J. Neural Transm. Suppl. 52: 287-300.

    Google Scholar 

  • Speiser, Z.,Mayk, A.,Eliash, S., andCohen, S. (1999). Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J. Neural Transm. 106: 593-606.

    Google Scholar 

  • Sterling, J.,Veinberg, A.,Lerner, D.,Goldenberg, W.,Levy, R.,Youdim, M., andFinberg, J. (1998). (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B. J. Neural Transm. Suppl. 52: 301-305.

    Google Scholar 

  • Tatton, W. G.,Ju, W. Y.,Holland, D. P.,Tai, C., andKwan, M. (1994). (—)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63: 1572-1575.

    Google Scholar 

  • Wadia, J. S.,Chalmers-Redman, R. M. E.,Ju,W. J. H.,Carlile, G.W.,Phillips, J. L.,Fraser, D., andTatton, W. G. (1998). Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (—)-deprenyl. J. Neurosci. 18: 932-947.

    Google Scholar 

  • Weinstock, M. (1999). Selectivity of cholinesterase inhibition: Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 12: 307-323.

    Google Scholar 

  • Weinstock, M.,Bejar, C.,Wang, R-H.,Poltyrev, T.,Gross, A.,Finberg, J. P. M., andYoudim, M. B. H. (2000b). TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. Suppl. 60: 157-169.

    Google Scholar 

  • Weinstock, M.,Goren, T., andYoudim, M. B. H. (2000a). Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Dev. Drug Res. 50: 216-223.

    Google Scholar 

  • Weinstock, M.,Kirschenbaum-Slager, N.,Lazarovici, P.,Bejar, C.,Youdim, M. B. H., andShoham, S. (2001). Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann. N. Y. Acad. Sci. 939: 148-161.

    Google Scholar 

  • Whitehouse, P. J.,Price, D. L.,Struble, R.G.,Clark, A.W.,Coyle, J.T., andDelon, M. R. (1982). Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215: 1237-1239.

    Google Scholar 

  • Youdim, M. B. H.,Gross, A., andFinberg, J. P. (2001a). Rasagiline [N-propargyl-1R(C)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132: 500-506.

    Google Scholar 

  • Youdim, M. B. H.,Wadia, A.,Tatton, W., and Weinstock, M. (2001b). The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated toMAOinhibition incell culture and in vivo. Ann. N. Y. Acad. Sci. 939: 450-458.

    Google Scholar 

  • Youdim, M. B. H., andWeinstock, M. (2002). Novel neuroprotective anti-Alzheimer drug with antidepressant activity derived from the anti-Parkinson drug, rasagiline. J. Pharm. Pharmacol.

Download references

Author information

Authors and Affiliations

  1. Eve Topf and National Parkinson Foundation Centers for Neurodegenerative Diseases Research, Department of Pharmacology, Technion-Faculty of Medicine, Haifa, Israel

    Moussa B. H. Youdim

  2. Department of Pharmacology, Hebrew University Medical Center, Jerusalem, Israel

    Marta Weinstock

Authors
  1. Moussa B. H. Youdim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marta Weinstock
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Youdim, M.B.H., Weinstock, M. Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate]. Cell Mol Neurobiol 21, 555–573 (2001). https://doi.org/10.1023/A:1015131516649

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015131516649

Search

Navigation